References
- Brurok H, Ardenkjær-Larsen JH, Hansson G, et al. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties. Bioch Biophys Res Comm 1999; 254: 768–72
- Karlsson JOG, Brurok H, Towart R, Jynge P. Letter to the Editor. The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide mimetic activity. Cancer Res 2006; 66: 598
- Towart R, Jynge P, Refsum H, Karlsson JOG. Manganese dipyridoxyl diphosphate protects against acute anthracycline induced cardiotoxicity in mice. Arch Pharmacol 1998; 358(Suppl 2)R626
- Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948–56
- Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the thereapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006; 98: 236–44
- Sørbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003; 42: 827–31
- de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47
- Shimizu T, Satoh T, Tamura K, et al. Oxaliplatin /fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: Post-approval Japanese population experience. T Oncol 2007; 12: 218–23
- Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed 2004; 17: 544–53